Patients' Genes May Influence Quality of Life After Cancer Chemotherapy

Impacts of GRIN3A, GRM6 and TPH2 genetic polymorphisms on quality of life in methadone maintenance therapy population

“…In addition to these socioeconomic factors, biological pathways and neurotransmitters such as serotonergic and glutamatergic pathways have been identified as related to various QoL domains, including pain, fatigue, and emotional and social functioning[ 44 – 47 ]. Since it was proposed in 2004, the hypothesis that QoL has a genetic basis has been supported by several studies[ 48 , 49 ]. In the present study, we discovered that TPH2 rs1487275-G was significantly associated with the QoL of the MMT population after adjustment of clinical and socioeconomic factors, supported the hypothesis that QoL has a genetic basis.…”

North Central Cancer Treatment Group—Achievements and Perspectives

“…114–116 Data derived from the practice-changing colorectal cancer trial N9741 to test this hypothesis was presented in a plenary session at ASCO in 2004. 117,118 Results provided preliminary evidence of a genetic component within a patient’s response to a cancer diagnosis, even before treatment is initiated. Genetic variants in DPYD*5 and TYMS TSER were associated with differences in QOL.…”

Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer

“…With the intersection and integration of molecular biology, psychology, and epidemiology, most researchers agree that individual physiology, psychology, and behavior are the result of both genetic and environmental factors. In 2004, Hampton et al proposed that the QoL has a certain genetic basis, and gene technology should be integrated into the study of QoL [ 6 , 7 ]. In 2014, a review summarized the biological pathways, candidate genes, and molecular markers related to the QoL.…”